USA – US biotech giant Gilead Sciences announced that it has exercised its options on three Arcus Biosciences investigational cancer molecule development and explore treatment combinations across the two portfolios…
Read MoreGilead pays up to retain rights to Arcus Biosciences cancer drugs
